Login to Your Account

Pharma: Clinic Roundup

Thursday, April 26, 2012

• UCB SA, of Brussels, Belgium, reported post-hoc analyses of pivotal trials of Neupro (rotigotine transdermal system) in patients with restless legs syndrome (RLS)/Willis Ekbom disease, showing improvements with rotigotine vs. placebo in most of the single items from the International RLS Study Group Rating Scale scores, which measured sensory-motor dysfunction, severity of sleep disturbance and the impact of RLS on daily activities. Those and other findings were presented at the American Academy of Neurology meeting in New Orleans.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription